Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,328.00
Bid: 12,346.00
Ask: 12,348.00
Change: -228.00 (-1.82%)
Spread: 2.00 (0.016%)
Open: 12,512.00
High: 12,554.00
Low: 12,328.00
Prev. Close: 12,556.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

3 Aug 2015 15:00

RNS Number : 9096U
AstraZeneca PLC
03 August 2015
 



Transparency Directive

Voting Rights and Capital

 

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 July 2015 the issued share capital of AstraZeneca PLC with voting rights is 1,263,665,297 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,263,665,297.

 

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

 

 

A C N Kemp

Company Secretary

3 August 2015

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRLLFFVTFIVIIE
Date   Source Headline
26th May 202010:30 amRNSDirector/PDMR Shareholding
22nd May 20207:00 amRNSEnhertu US orphan designation in gastric cancer
21st May 20207:00 amRNSAstraZeneca advances response to COVID-19 outbreak
20th May 20207:00 amRNSLynparza approved in the US for prostate cancer
18th May 20207:00 amRNSEnhertu US Breakthrough status for lung cancer
18th May 20207:00 amRNSBevespi Aerosphere approved in China for COPD
11th May 20207:00 amRNSEnhertu designated gastric cancer BTD
11th May 20207:00 amRNSLynparza gets broader US ovarian cancer approval
11th May 20207:00 amRNSBrazikumab rights recovered by AstraZeneca
6th May 20207:00 amRNSFarxiga approved by FDA for heart failure (HFrEF)
1st May 20203:00 pmRNSTotal Voting Rights
29th Apr 20204:00 pmRNSResult of AGM
29th Apr 20207:00 amRNSAZN: first-quarter 2020 results
24th Apr 20207:00 amRNSLynparza shows overall survival in prostate cancer
17th Apr 202011:00 amRNSChanges to arrangements for AGM
14th Apr 20207:00 amRNSKoselugo (selumetinib) approved in the US for NF1
14th Apr 20207:00 amRNSTagrisso adjuvant trial overwhelmingly positive
2nd Apr 20207:00 amRNSAstraZeneca divestment of Movantik completed
1st Apr 20203:00 pmRNSTotal Voting Rights
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:01 amRNSImfinzi approved in US for small cell lung cancer
30th Mar 20207:00 amRNSFarxiga CKD trial early stop for positive efficacy
26th Mar 20207:00 amRNSLokelma approved in Japan for hyperkalaemia
26th Mar 20207:00 amRNSDirector/PDMR Shareholding
24th Mar 20204:41 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 202012:02 pmRNSPrice Monitoring Extension
23rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
23rd Mar 202012:08 pmRNSSecond Price Monitoring Extn
23rd Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:20 amRNSSecond Price Monitoring Extn
20th Mar 202010:15 amRNSPrice Monitoring Extension
20th Mar 20207:00 amRNSDirector/PDMR Shareholding
19th Mar 20207:00 amRNSLynparza granted orphan drug designation in Japan
17th Mar 20207:00 amRNSImfinzi confirmed overall survival in CASPIAN
13th Mar 20204:35 pmRNSPrice Monitoring Extension
12th Mar 202011:00 amRNSNotice of AGM
12th Mar 20207:00 amRNSUpdate on Phase III GY004 trial for cediranib
10th Mar 20207:00 amRNSDirector/PDMR Shareholding
6th Mar 20207:00 amRNSUpdate on Phase III DANUBE trial in bladder cancer
4th Mar 20207:00 amRNSFiling of Form 20-F with SEC
3rd Mar 202011:00 amRNSAnnual Financial Report
2nd Mar 20203:00 pmRNSTotal Voting Rights
2nd Mar 20207:00 amRNSDivestment of hypertension medicines completed
27th Feb 20207:00 amRNSDirector/PDMR Shareholding
25th Feb 20207:00 amRNSAstraZeneca divests global rights to Movantik
19th Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20207:00 amRNSAZN: Full-year and Q4 2019 results
3rd Feb 20203:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.